Alembic‍‌‍‍‌‍‌‍‍‌‍‌‍‍‌‍‌‍‍‌‍‌‍‍‌‍‌‍‍‌ Pharmaceuticals Q2FY26 Results: Profit Grew 19.6% Year-over-Year to ₹184.7 Crore, Revenue Rose 15.9%

Vadodara, 4 November 2025: Alembic Pharmaceuticals Limited (NSE: APLLTD, BSE: 533573) announced strong financial results for the quarter ended September 30, 2025 (Q2FY26), reflecting consistent growth across both domestic and international markets.

Robust Financial Performance

The company reported a consolidated revenue from operations of ₹1,910.15 crore, marking a 15.9% year-on-year (YoY) and 11.7% quarter-on-quarter (QoQ) growth. Total income rose to ₹1,917.06 crore, while profit before tax increased 34.2% YoY to ₹223.72 crore. The net profit climbed to ₹184.71 crore, reflecting a 19.6% YoY and 20.3% QoQ rise. Correspondingly, earnings per share (EPS) improved to ₹9.40, compared to ₹7.79 in the same period last year.

For the first half of FY26 (ending September 2025), the company recorded a consolidated revenue of ₹3,620.87 crore, representing a 12.8% YoY increase. The net profit also advanced by 21.7% YoY to ₹339.09 crore, underscoring the sustained growth momentum across its operations.

Operating Performance

Alembic Pharmaceuticals’ strong performance in Q2FY26 was driven by the domestic formulations division and the revival of its international business. The domestic formulations segment benefited from new product launches and an increase in prescription volumes.

Following the acquisition of a UK-based research and development (R&D) entity, which added ₹221.97 crore to intangible assets, the company’s US generics unit continued to maintain stable performance during the quarter.

Commenting on the results, Chairman and CEO Chirayu Amin stated that the company aims to expand its global R&D network and accelerate innovation-led growth. He further emphasised that operational efficiency and cost management would remain key focus areas to sustain healthy margins through FY26.

Stock Market Reaction

After the announcement of the results, Alembic Pharmaceuticals’ share price closed at ₹950.00 on November 4, 2025. During the session, the stock reached an intraday high of ₹984.90, nearing its 52-week high of ₹1,152.00. The upward movement in the stock price reflected investor confidence in Alembic’s improved profitability and its strategic focus on global expansion and innovation-led growth.

Outlook

The company’s strategy to utilise retained earnings for funding innovation, research, and global market expansion is set to be the key driver of Alembic’s sustainable growth. The integration of the recently acquired UK-based R&D facility is expected to strengthen its pipeline of high-value products. With consistent demand across key markets, Alembic remains well-positioned to maintain earnings stability in the upcoming quarters.

REF: https://nsearchives.nseindia.com/corporate/APLLTD_04112025143003_Outcome_Board_Meeting.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations